Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 79

Results For "IFF"

1272 News Found

Innovative AI software for detection of pancreatic diseases
Digitisation | May 18, 2022

Innovative AI software for detection of pancreatic diseases

As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications


BDR Pharma receives Rs. 685 crore of PE investment
News | May 17, 2022

BDR Pharma receives Rs. 685 crore of PE investment

Multiples is the first private equity (PE) investor in the company


Aster DM Healthcare partners with Skye Air Mobility for drone delivery
News | May 17, 2022

Aster DM Healthcare partners with Skye Air Mobility for drone delivery

Following the successful completion of the 7day BVLOS trials, Skye Air targets to undertake approximately 80 flights, each carrying blood samples and medicines for Aster Clinics


Moderna announces advancements in mRNA platform science for application across multiple diseases
Biotech | May 17, 2022

Moderna announces advancements in mRNA platform science for application across multiple diseases

Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery


Antengene announces commercial availability of Xpovio in China
Biotech | May 16, 2022

Antengene announces commercial availability of Xpovio in China

The drug will be available in 600 hospitals and 105 DTPs


GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia
Biotech | May 16, 2022

GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia

They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights


Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData
Biotech | May 15, 2022

Tirzepatide has potential to drive weight loss market dramatically, observes GlobalData

Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022


USFDA approves novel, dual-targeted treatment for type 2 diabetes
Drug Approval | May 15, 2022

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated


Sarclisa (isatuximab) combination provides unprecedented median progression-free survival
Biotech | May 15, 2022

Sarclisa (isatuximab) combination provides unprecedented median progression-free survival

The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone